Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
QuintilesIMS
Farmers Insurance
Novartis
Chinese Patent Office
Federal Trade Commission
Daiichi Sankyo
Baxter
Cipla
Mallinckrodt

Generated: January 19, 2018

DrugPatentWatch Database Preview

ZYPREXA Drug Profile

« Back to Dashboard

Which patents cover Zyprexa, and what generic alternatives are available?

Zyprexa is a drug marketed by Lilly and Eli Lilly Co and is included in four NDAs. There are two patents protecting this drug.

This drug has twenty-six patent family members in twenty-three countries.

The generic ingredient in ZYPREXA is olanzapine pamoate. There are thirty-three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the olanzapine pamoate profile page.
Drug patent expirations by year for ZYPREXA
Pharmacology for ZYPREXA

US Patents and Regulatory Information for ZYPREXA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly ZYPREXA olanzapine INJECTABLE;INTRAMUSCULAR 021253-001 Mar 29, 2004 AP RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Lilly ZYPREXA ZYDIS olanzapine TABLET, ORALLY DISINTEGRATING;ORAL 021086-001 Apr 6, 2000 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Lilly ZYPREXA ZYDIS olanzapine TABLET, ORALLY DISINTEGRATING;ORAL 021086-004 Apr 6, 2000 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Lilly ZYPREXA olanzapine TABLET;ORAL 020592-003 Sep 30, 1996 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Lilly ZYPREXA olanzapine TABLET;ORAL 020592-002 Sep 30, 1996 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Lilly ZYPREXA olanzapine TABLET;ORAL 020592-006 Sep 9, 1997 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Lilly ZYPREXA ZYDIS olanzapine TABLET, ORALLY DISINTEGRATING;ORAL 021086-002 Apr 6, 2000 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Lilly ZYPREXA olanzapine TABLET;ORAL 020592-004 Sep 30, 1996 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Lilly ZYPREXA ZYDIS olanzapine TABLET, ORALLY DISINTEGRATING;ORAL 021086-002 Apr 6, 2000 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Eli Lilly Co ZYPREXA RELPREVV olanzapine pamoate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173-003 Dec 11, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for ZYPREXA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly ZYPREXA olanzapine TABLET;ORAL 020592-005 Sep 9, 1997 ➤ Subscribe ➤ Subscribe
Lilly ZYPREXA olanzapine TABLET;ORAL 020592-006 Sep 9, 1997 ➤ Subscribe ➤ Subscribe
Lilly ZYPREXA olanzapine TABLET;ORAL 020592-001 Sep 30, 1996 ➤ Subscribe ➤ Subscribe
Lilly ZYPREXA olanzapine TABLET;ORAL 020592-005 Sep 9, 1997 ➤ Subscribe ➤ Subscribe
Lilly ZYPREXA olanzapine INJECTABLE;INTRAMUSCULAR 021253-001 Mar 29, 2004 ➤ Subscribe ➤ Subscribe
Lilly ZYPREXA olanzapine TABLET;ORAL 020592-002 Sep 30, 1996 ➤ Subscribe ➤ Subscribe
Lilly ZYPREXA olanzapine TABLET;ORAL 020592-002 Sep 30, 1996 ➤ Subscribe ➤ Subscribe
Lilly ZYPREXA olanzapine TABLET;ORAL 020592-004 Sep 30, 1996 ➤ Subscribe ➤ Subscribe
Lilly ZYPREXA olanzapine TABLET;ORAL 020592-006 Sep 9, 1997 ➤ Subscribe ➤ Subscribe
Lilly ZYPREXA olanzapine TABLET;ORAL 020592-001 Sep 30, 1996 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for ZYPREXA

Supplementary Protection Certificates for ZYPREXA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB96/058 United Kingdom ➤ Subscribe PRODUCT NAME: OLANZAPINE OPTIONALLY IN THE FORM OF AN ACID ADDITION SALT; REGISTERED: UK EU/1/96/022/001 19960927; UK EU/1/96/022/002 19960927; UK EU/1/96/022/003 19960927; UK EU/1/96/022/004 19960927; UK EU/1/96/022/005 19960927; UK EU/1/96/022/006 19960927; UK EU/1/96/022/007 19960927; UK EU/1/96/022/008 19960927; UK EU/1/96/022/009 19960927; UK EU/1/96/022/010 19960927
70015 Netherlands ➤ Subscribe PRODUCT NAME: OLANZAPINE, DESGEWENST IN DE VORM VAN EEN ZUURADDITIEZOUT; REGISTRATION NO/DATE: EU/1/96/022/001 - EU/1/96/022/010 19960927
C0012 Belgium ➤ Subscribe PRODUCT NAME: OLANZAPINE; REGISTRATION NO/DATE: EU/1/96/022/001 19960927
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
UBS
Healthtrust
Colorcon
Federal Trade Commission
Citi
QuintilesIMS
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot